A comprehensive view of AstraZeneca AB. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca’s injectable Evusheld COVID-19 antibody ineffective against omicron GA.4.6 warns FDA; AstraZeneca reports BA4.6 accounts for 6.2% of infections globally while dominant BA.5 subvariant accounts for 85% of current infections
Published: October 05, 2022 by FiercePharma
Japan joins US, EU in approving AstraZeneca’s injectable asthma drug Tezspire tezepelumab, developed with Amgen; Tezspire treats severe, refractory bronchial asthma that can't be controlled with inhaled corticosteroids, long-term maintenance therapies
Published: September 28, 2022 by SeeNews Pharmaceuticals
AstraZeneca to end work on experimental cholesterol drug ION449 under development with partner Ionis; the two firms still working together on kidney drug ION532, fatty liver disease drugs ION839 and ION455, cancer therapy ION736
Published: September 26, 2022 by SeeNews Pharmaceuticals
AstraZeneca’s long-acting injectable COVID-19 antibody therapy Evusheld tixagevimab and cilgavimab receives approval in EU; drug treats patients who don’t require supplemental oxygen but are at increased risk to develop severe disease
Published: September 22, 2022 by SeeNews Pharmaceuticals
AstraZeneca reports EU advisory committee recommends its injectable Evusheld tixagevimab/cilgavimab antibody therapy for approval; treatment aimed at non-hospitalized COVID-19 patients who have increased risk for developing severe disease
Published: September 19, 2022 by SeeNews Pharmaceuticals

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count